Fri, Jul 25, 2014, 11:58 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Allergan Inc. Message Board

fastestgrowingstocks 2 posts  |  Last Activity: Feb 8, 2012 7:31 PM Member since: Feb 8, 2012

    Wednesday, February 01, 2012

    .: Followup to REPCF cure for baldness. Interview with CEO :.

    NBT Two-Minute Drill Interview with David Hall, CEO of Replicel Life Sciences

    We recently interviewed David Hall, CEO of Replicel Life Sciences, Inc., on the upcoming Phase I/IIa clinical trial results “reveal” for their cell-based hair regeneration technology some 90 or so days away.

    With positive results expected from their current Phase I/IIa trial, Replicel will move immediately into a 100-patient dosing trial from which it hopes to build an overwhelming set of successful data for the patented RepliCel™ procedure for minimally invasive hair cell growth and implantation.

    With two successful data-sets in hand, Replicel intends to sell its entire hair growth and implantation business to the highest Big Pharma/Big Bio bidder. NBT analyses the value of their follicular regeneration business at about $500 million—or more than $10 a share with an expected 10 million share dilution from money raising activities in 2012.


  • fastestgrowingstocks by fastestgrowingstocks Feb 8, 2012 7:23 PM Flag

    at this website that specializes in fast growing stocks under 5.

    discusses ramping demand for graphite, especially in China

170.06-0.51(-0.30%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.